
Ranibizumab monotherapy showed stronger effects on area of retinal neovascularization (NV) reduction while offering better visual acuity (VA) results than panretinal laser photocoagulation (PRP) monotherapy during the first 12 months of the PRIDE study. The second year of PRIDE was an observational, non‐interventional follow‐up, performed to evaluate long‐term anatomical and functional outcomes in proliferative diabetic retinopathy (PDR) patients under real‐life conditions, prior to the approval of ranibizumab for PDR. Seventy‐three PDR patients (28 from the ranibizumab group; 20 from the PRP group; 25 from the combination group) were included in the observational follow‐up phase and treated at the investigators discretion...
Like
Save
Share